<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>俄罗斯的Sputnik V疫苗在早期分析中看起来不错 Russia’s Sputnik V vaccine looks good in early analysis</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">Russia’s Sputnik V vaccine looks good in early analysis<br/>俄罗斯的Sputnik V疫苗在早期分析中看起来不错 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-02-06 21:07:46</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/2/8bd49f55fc6934add9629f03e496c9c2.jpg"><img src="http://img2.diglog.com/img/2021/2/8bd49f55fc6934add9629f03e496c9c2.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>Yesterday, the people behind Russia&#39;s leading vaccine, termed Sputnik V, issued a preliminary analysis of its function. The news was quite good: while the trial is ongoing and final results will have to wait, the interim data suggests that the vaccine could be over 90 percent effective.</p><p>昨天，被称为俄罗斯人造卫星V的俄罗斯领先疫苗背后的人们发表了对其功能的初步分析。这个消息真是好消息：尽管试验仍在进行中，最终结果将不得不等待，但中期数据表明该疫苗的有效性可能超过90％。</p><p> Sputnik V is based on similar technology to the vaccines being developed by Johnson &amp; Johnson and the Oxford/AstraZeneca collaboration. Strikingly, however, the preliminary efficiency is quite a bit higher than those vaccines are showing, and it&#39;s not clear how the Sputnik-specific features could account for the difference.</p><p> Sputnik V基于与强生公司开发的疫苗类似的技术。约翰逊和牛津/阿斯利康的合作。然而，引人注目的是，初步效率比那些疫苗所显示的要高得多，并且尚不清楚人造卫星特有的特征如何解释这种差异。</p><p>  The results come out of a Phase III clinical trial involving roughly 21,000 participants being run in Moscow. Participants were all over the age of 18, hadn&#39;t received other vaccinations recently, weren&#39;t pregnant or drug users, and met a number of other criteria. PCR-based SARS-CoV-2 tests were performed at enrollment, and participants were also tested for the presence of antibodies against the virus.</p><p>  该结果来自一项在莫斯科进行的大约21,000名参与者的III期临床试验。参与者都在18岁以上，最近没有接受过其他疫苗接种，没有怀孕或吸毒，并且还符合其他一些条件。在招募时进行了基于PCR的SARS-CoV-2测试，还对参与者进行了针对该病毒的抗体测试。</p><p> While the data gathering was integrated with the Russian health system—which allowed researchers to obtain data from any participant who got health care within the Moscow area—the trial itself was run by a commercial third party based in the Netherlands.</p><p> 尽管数据收集已与俄罗斯卫生系统集成在一起，使研究人员可以从莫斯科地区获得卫生保健的任何参与者那里获取数据，但该试验本身是由位于荷兰的商业第三方进行的。</p><p> The participants were divided so that three times as many received the vaccine instead of a placebo. This assignment was randomized, and everyone involved was kept in the dark about who got what. While the full trial will continue for several more months, the researchers took advantage of the fact that the vaccine requires two doses separated by 21 days to do an interim analysis of how effective the first dose was. So researchers repeated the PCR and antibody tests, and they checked for its efficacy after a single dose.</p><p> 对参与者进行了划分，以使接受疫苗的人数是安慰剂的三倍。这项任务是随机的，每个参与人员都不知道谁得到了什么。虽然整个试验将继续进行数月，但研究人员利用了疫苗需要两次疫苗间隔21天这一事实，对第一剂疫苗的有效性进行了中期分析。因此，研究人员重复了PCR和抗体测试，并在单剂后检查了其功效。</p><p>    The results were remarkably good. There were 16 cases among those who had received the vaccine, compared to 62 cases among those who got a placebo. But remember there were three times as many people in the vaccine group, which makes the effectiveness even higher; the researchers calculated it at just over 90 percent. None of the people who received the vaccine had cases that hit the researchers&#39; definition of moderate or severe, while 20 people in the placebo group did. This suggests that the vaccine also lowers the chances of severe illness (something that&#39;s been seen with other vaccines).</p><p>    结果非常好。接种疫苗的人中有16例，而使用安慰剂的人中有62例。但是请记住，疫苗组的人数是疫苗组的三倍，这使得疫苗的效力更高。研究人员计算得出，这一比例刚刚超过90％。接种疫苗的人都没有感染研究人员的病例。定义为中度或重度，而安慰剂组为20人。这表明该疫苗还降低了重病的几率（其他疫苗已经发现了这种情况）。</p><p> At 21 days, nearly all of those who received the vaccine had antibodies against SARS-CoV-2, as you&#39;d expect. But 15 percent of those in the placebo group  also had antibodies against the virus, suggesting that they&#39;d had asymptomatic cases in the mean time. Based on the trial&#39;s protocol, these weren&#39;t counted as COVID-19 cases for the purpose of the statistics.</p><p> 正如您所期望的，在第​​21天，几乎所有接受疫苗的人都具有针对SARS-CoV-2的抗体。但是，安慰剂组中有15％的人也有针对该病毒的抗体，这表明他们在此期间无症状。根据该试验方案，出于统计目的，这些不算为COVID-19病例。 </p><p> A number of people had already been identified as having SARS-CoV-2 ahead of the 21-day time point, and they weren&#39;t included in the analysis that suggested a 90 percent efficacy. That&#39;s because these infections could have started before the vaccine had a chance to generate any significant immune response. If these are included, however, the efficacy of the vaccine drops a bit, to 73 percent.</p><p>在21天的时间点之前，已经确定了许多人患有SARS-CoV-2，并且未将其包括在表明90％疗效的分析中。那是因为这些感染可能是在疫苗有机会产生任何重大免疫反应之前开始的。但是，如果包括这些，则疫苗的功效会降低一点，降至73％。</p><p>  There was one death each in the vaccine and placebo groups due to random events in the first 21 days of the study. And two people who were vaccinated developed severe COVID-19 within a week of the vaccination and eventually died. Due to the timing of the onset of symptoms there, the researchers estimate that the deceased were probably already infected when they were vaccinated, but the virus hadn&#39;t built up to levels that were detectable via PCR.</p><p>  在研究的前21天，由于随机事件，疫苗和安慰剂组各有1人死亡。接种疫苗的两个人在接种疫苗后一周内出现了严重的COVID-19，最终死亡。由于出现症状的时间安排，研究人员估计死者在接种疫苗时可能已经感染了病毒，但病毒的累积量尚未达到可通过PCR检测到的水平。</p><p>    Adverse effects were typical of those caused by effective vaccines: fevers, muscle aches, and fatigue were common. When more serious adverse events were considered, however, they were more common in the placebo group (0.4 percent) than in the vaccine recipients (0.3 percent).</p><p>    不良反应是有效疫苗引起的典型不良反应：发烧，肌肉酸痛和疲劳很常见。但是，如果考虑到更严重的不良事件，则在安慰剂组（0.4％）比在疫苗接种者（0.3％）中更常见。</p><p>  As mentioned above, the Sputnik V vaccine uses the same technology tried by other companies: it places a key coronavirus protein into a harmless cold virus named adenovirus. The unique feature of Sputnik V is that it used two doses, with different strains of adenovirus in each dose. This limits the chance of the immune reaction being focused on the adenovirus itself, instead of the coronavirus protein it carries.</p><p>  如上所述，Sputnik V疫苗使用了其他公司尝试过的相同技术：将一种重要的冠状病毒蛋白放入一种无害的感冒病毒，即腺病毒。 Sputnik V的独特之处在于它使用了两次剂量，每次剂量使用不同的腺病毒株。这限制了免疫反应聚焦于腺病毒本身而不是其携带的冠状病毒蛋白的机会。</p><p> But that advantage wouldn&#39;t be at play with a single dose, meaning we might expect similar effectiveness to that seen from the two other adenovirus-based vaccines. In fact, given that the immune response is likely to still be ramping up at 21 days, we&#39;d probably expect to see reduced effectiveness from any vaccine using the study protocol done here. Yet Sputnik V seems to be  significantly more effective than the offerings of Johnson &amp; Johnson or AstraZeneca.</p><p> 但是，单剂量就不会发挥这种优势，这意味着我们可以期望获得与其他两种基于腺病毒的疫苗相似的效果。实际上，考虑到在21天时免疫反应可能仍会加剧，我们可能期望使用此处完成的研究方案从任何疫苗中看到的有效性降低。然而，人造卫星V似乎比强生公司的产品要有效得多。约翰逊或阿斯利康。</p><p>  On its own, that would be unexpected. But the results are arriving after a somewhat bizarre history for Sputnik V. Concerns include  suggestions of manipulated data in the paper describing the Phase I trials of the vaccine, along with Russia starting widespread use of the vaccine  ahead of the clinical trial data. Russia also went on to approve  a second untested vaccine for good measure. So there&#39;s certainly a fair number of reasons to be skeptical of Russia&#39;s vaccine approach by this point.</p><p>  就其本身而言，这将是意外的。但结果是在人造卫星V出现了一段奇异的历史之后得出的。关注的焦点包括在描述疫苗I期试验的论文中操纵数据的建议，以及俄罗斯在临床试验数据之前开始广泛使用疫苗。俄罗斯还继续批准了第二种未经测试的疫苗。因此，到那时，肯定有很多理由对俄罗斯的疫苗方法表示怀疑。</p><p> Still, given the reasonable successes generated by other adenovirus-based vaccines, don&#39;t be surprised if Sputnik V works. And there&#39;s still the prospect that using two different virus strains will make the vaccine more effective than others based on this technology. But we&#39;ll have to wait for the full trial data to know whether that&#39;s the case—along with some clear answers about the odd history of these trials.</p><p> 尽管如此，考虑到其他基于腺病毒的疫苗所取得的合理成功，如果人造卫星V能够工作，也不要感到惊讶。而且仍然有前景，即使用两种不同的病毒株将使疫苗比其他基于该技术的疫苗更有效。但是，我们必须等待完整的试验数据才能知道情况是否如此-以及有关这些试验奇数历史的一些明确答案。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://arstechnica.com/science/2021/02/russias-sputnik-v-vaccine-looks-good-in-early-analysis/">https://arstechnica.com/science/2021/02/russias-sputnik-v-vaccine-looks-good-in-early-analysis/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/俄罗斯/">#俄罗斯</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/sputnik/">#sputnik</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>